Skip to main content

Table 2 Laboratory findings of patients before PMX-DHP therapy

From: Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias

 

Survivors (n = 5)

Non-survivors (n = 9)

p value

P/F ratio

242 (147.6–262.5)

138.6 (48.6–242.7)

0.042*

APACHE II

12 (9–15)

13 (11–17)

0.139

HRCT score, %

247.8 (191.8–361.2)

231.4 (177.0–309.6)

0.463

WBC, /μL

11,100 (10600–19,400)

10,000 (3300–15,600)

0.124

Neut, /μL

10,038 (7825–17,188)

9016 (2670–13,603)

0.257

Lym, /μL

1707 (214–2775)

530 (0–1310)

0.257

Plt (× 104), μL

31.8 (29.7–40.7)

21.9 (9.4–26.8)

0.003*

LDH, U/L

332 (171–462)

468 (343–1104)

0.014*

CK, U/L

69 (14–335)

65 (11–514)

0.689

CRP, mg/dL

4.08 (0.14–13)

0.56 (0.13–4.22)

0.386

KL-6, U/mL

906 (390–2725)

2024 (403–4730)

0.125

SP-D, ng/mL

150.1 (116.6–339.9)

69.9 (15–341)

0.039*

Ferritin, ng/mL

180.6 (13–701.3)

1260.3 (600.8–4362)

0.011*

HMGB-1, ng/mL

9.6 (3.6–37.4)

13.2 (2.7–30.7)

0.942

  1. Dates are expressed as group median values. The p values refer to comparisons between the survivors and non-survivors groups. *: p value <0.05
  2. P/F, arterial partial pressure of oxygen/fraction of inspired oxygen; WBC white blood cells, Neut neutrophils, Lym lymphocytes, Plt platelets, LDH lactate dehydrogenase, CK creatine kinase, CRP C-reactive protein, KL-6 Krebs von den Lungen-6, SP-D Surfactant protein-D, HMGB-1 High-mobility group box protein 1